氨氯地平阿托伐他汀钙片和阿托伐他汀钙片治疗高血压并冠心病的优劣差异

Differences between amlodipine atorvastatin calcium tablets and atorvastatin calcium tablets in the treatment of hypertension and coronary heart disease

目的探讨氨氯地平阿托伐他汀钙片(商品名:多达一)和阿托伐他汀钙片(商品名:立普妥)治疗高血压并冠心病的优劣差异。方法 80例高血压伴冠心病患者,随机分为观察组和对照组,各40例。对照组口服立普妥,观察组口服复方制剂多达一。治疗后比较两组临床疗效[心血管不良事件和心电图(ECG)]、生化指标(血脂)以及药物不良反应(ADR)情况。结果治疗后,观察组心血管不良事件疗效总有效率(95.0%)高于对照组(77.5%),差异具有统计学意义(P<0.05)。治疗前两组高密度脂蛋白胆固醇、总胆固醇、甘油三酯及低密度脂蛋白胆固醇比较差异均无统计学意义(P>0.05)。治疗后,两组高密度脂蛋白胆固醇、总胆固醇、甘油三酯及低密度脂蛋白胆固醇均较治疗前改善,且观察组改善情况优于对照组,差异均具有统计学意义(P<0.05)。观察组ECG改善总有效率(95.0%)优于对照组(75.0%),差异具有统计学意义(P<0.05)。试验期间,两组均未发生严重ADR。结论对高血压伴冠心病的治疗,立普妥和多达一安全性相当,但复方制剂多达一比立普妥的临床疗效更好,更值得推广。

Objective To discuss the differences between amlodipine atorvastatin calcium tablets(trade name:Duodayi)and atorvastatin calcium tablets(trade name:Lipitor)in the treatment of hypertension and coronary heart disease.Methods A total of 80 patients with hypertension and coronary heart disease were randomly divided into observation group and control group,with 40 cases in each group.The control group received Lipitor,and the observation group received Duodayi.After treatment,the clinical efficacy[adverse cardiovascular events and electrocardiogram(ECG)],biochemical indicators(blood lipids)and adverse drug reactions(ADR)in two groups was compared.Results After treatment,the observation group had higher total effective rate(95.0%)than the control group(77.5%),and the difference was statistically significant(P<0.05).Before treatment,both groups had no statistically significant difference in high density lipoprotein,total cholesterol,triglycerides and low density lipoprotein cholesterol(P>0.05).After treatment,both groups had improved high density lipoprotein cholesterol,total cholesterol,triglycerides and low density lipoprotein cholesterol,and the observation group had better improvement than the control group.Their difference was statistically significant(P<0.05).The observation group had better ECG improvement(95.0%)than the control group(75.0%),and the difference was statistically significant(P<0.05).No serious ADR occurred in both groups during the trial.Conclusion Lipitor is as safe as Duodayi for the treatment of hypertensive coronary heart disease,but the clinical efficacy of compound preparation Duodayi is better than that of Lipitor,and it is worth popularizing.